Interview with Greg B. Scott, President & Founder, ChinaBio® LLC
This is our first meeting in Shanghai after being based in Beijing for two months – what if any are the differences between the two cities? At the top level,…
Address: ChinaBio® LLC Biotech VC Plaza Zhangjiang Hi-Tech Park 780 Cailun Road, Suite 822 Pudong New Area, Shanghai P.R. China 201203 ,China
Tel: -5823
Web: http://www.chinabiollc.com/
Since its founding in January, 2007, ChinaBio® LLC has rapidly launched a number of initiatives accelerating the globalization of China’s life science industry. ChinaBio has helped China companies raise nearly $500 million and global life science companies identify over 400 licensing and acquisition opportunities in China.
• Conferences: ChinaBio organizes the premier life science investment and partnering conferences in China, having attracted over 4,000 attendees. • Consulting: ChinaBio works with global life science companies and China entrepreneurs to define and execute a successful global strategy. • Transactions: ChinaBio helps companies secure partnerships and acquisitions and access private and government funding in China. • Publishing: ChinaBio® Today is the most widely read online and email newsletter on China’s life science industry.
This is our first meeting in Shanghai after being based in Beijing for two months – what if any are the differences between the two cities? At the top level,…
With nearly half of Chinese adults now suffering from myopia and age-related eye conditions on the rise, China is on the brink of an ophthalmology boom — a market set…
A summary of top stories from China’s pharma industry: Sciwind Biosciences presents promising trial data for its obesity contender; Simcere reaches approval for its Idorsia-partnered insomnia therapy; AstraZeneca inks AI-enabled…
Swapping the predictability of venture capital for the high-stakes volatility of biotech entrepreneurship, John Zhu set out to build something few in China had dared: a globally oriented biopharma with…
Ye Liu, CEO and cofounder of OcuMension Therapeutics, speaks about the challenges and triumphs of running one of China’s most ambitious ophthalmology-focused biopharmaceutical companies. Launched with USD 5 million and…
Building a biotech from the ground up is rarely the next step for someone who has led multinational pharmaceutical giants. Yet that was the challenge Pony Lu accepted when he…
2024 marks a moment of inflection for Harbour BioMed, as the company collect the rewards of a strong global execution. In this interview, Dr Jingsong Wang reflects on the strategic,…
As a result of its ageing demographic, China has seen a sharp rise in Alzheimer’s Disease (AD). The country’s AD patients over 60 already total some ten million and as…
This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers China’s USD 36.2bn in outbound licensing agreements, Henlius & EssexBio meeting Phase III endpoints, Organon acquiring US…
This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers the AACR 2025 ADC pipeline list from China, Puhe out-licensing global rights of a PRMT5 inhibitor to…
2024 was another groundbreaking year for Chinese medicine approvals. Writing in the March 2025 edition of DIA’s Global Forum magazine, Juan Valencia S. and Angel Shao of PharmCube explain how…
Illumina has been swept into the trade conflict between the US and China. After the Trump administration declared a 10 percent tariff on Chinese goods in February, Beijing retaliated by…
A roundup of some of the biggest stories coming out of China’s pharma industry, including the news that AstraZeneca may be seeing the other side of country’s probes; the counter-sanction…
See our Cookie Privacy Policy Here
